CLOs on the Move

GlycoMimetics

www.glycomimetics.com

 
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Christian Dinneen-Long
 Vice President and Corporate Counsel Profile

Similar Companies

EndGenitor Technologies

EndGenitor Technologies is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Maxim Health Information Services

Maxim Health Information Services is a Gardena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edifice Health

Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health.

Nkmax

NKMax America is harnessing the power of the body`s immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient`s ability to destroy abnormal cells.

Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company`s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic "off-the-shelf" cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.